Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy. We conducted ...
In the phase 1/2 trial for dapotamab deruxtecan an objective response rate (ORR) ranging from 21% to 25%, as assessed by independent central review, was observed in 159 patients with advanced or ...
Meanwhile, AZ has also licensed a TROP2-targeting ADC from Daiichi Sankyo – dapotamab deruxtecan – that it hopes will challenge Gilead Sciences’ rival ADC Trodelvy (sacituzumab govitecan ...
(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...
The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain metastases in HER2-positive breast cancer. With a median progression-free survival of 17.3 months and ...
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd ...
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback